These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 17826691)

  • 1. The significance of mitochondrial toxicity testing in drug development.
    Dykens JA; Will Y
    Drug Discov Today; 2007 Sep; 12(17-18):777-85. PubMed ID: 17826691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
    Dykens JA; Marroquin LD; Will Y
    Expert Rev Mol Diagn; 2007 Mar; 7(2):161-75. PubMed ID: 17331064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico prediction of mitochondrial toxicity by using GA-CG-SVM approach.
    Zhang H; Chen QY; Xiang ML; Ma CY; Huang Q; Yang SY
    Toxicol In Vitro; 2009 Feb; 23(1):134-40. PubMed ID: 18940245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of mitochondrial dysfunction and drug safety.
    Nadanaciva S; Will Y
    IDrugs; 2009 Nov; 12(11):706-10. PubMed ID: 19844857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA boxed warnings: how to prescribe drugs safely.
    O'Connor NR
    Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates.
    Gwathmey JK; Tsaioun K; Hajjar RJ
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):647-60. PubMed ID: 19442031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays.
    Nadanaciva S; Bernal A; Aggeler R; Capaldi R; Will Y
    Toxicol In Vitro; 2007 Aug; 21(5):902-11. PubMed ID: 17346924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A testing approach based on tiny doses still awaits big results.
    Coombs A
    Nat Med; 2008 Aug; 14(8):796. PubMed ID: 18685584
    [No Abstract]   [Full Text] [Related]  

  • 10. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 11. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of juvenile toxicity.
    Barrow PC; Barbellion S; Stadler J
    Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The acute extracellular flux (XF) assay to assess compound effects on mitochondrial function.
    Wang R; Novick SJ; Mangum JB; Queen K; Ferrick DA; Rogers GW; Stimmel JB
    J Biomol Screen; 2015 Mar; 20(3):422-9. PubMed ID: 25381255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast models of human mitochondrial diseases: from molecular mechanisms to drug screening.
    Schwimmer C; Rak M; Lefebvre-Legendre L; Duvezin-Caubet S; Plane G; di Rago JP
    Biotechnol J; 2006 Mar; 1(3):270-81. PubMed ID: 16897707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new FDA pregnancy labeling requirements for drugs.
    Frederiksen MC
    J Midwifery Womens Health; 2011; 56(3):303-7. PubMed ID: 21535377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real life juvenile toxicity case studies: the good, the bad and the ugly.
    De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
    Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A miniaturized homogenous assay of mitochondrial membrane potential.
    Vongs A; Solly KJ; Kiss L; Macneil DJ; Rosenblum CI
    Assay Drug Dev Technol; 2011 Aug; 9(4):373-81. PubMed ID: 21294696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Black box warnings in prescription drug labeling: results of a survey of 206 drugs.
    Beach JE; Faich GA; Bormel FG; Sasinowski FJ
    Food Drug Law J; 1998; 53(3):403-11. PubMed ID: 10346718
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk we bear: the effects of review speed and industry user fees on new drug safety.
    Olson MK
    J Health Econ; 2008 Mar; 27(2):175-200. PubMed ID: 18207263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.